FMP

FMP

Enter

SEEL - Seelos Therapeutics,...

Financial Summary of Seelos Therapeutics, Inc.(SEEL), Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development an

photo-url-https://financialmodelingprep.com/image-stock/SEEL.png

Seelos Therapeutics, Inc.

SEEL

NASDAQ

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

0.84 USD

-0.0199 (-2.37%)

About

ceo

Dr. Raj Mehra J.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://seelostherapeutics.com

exchange

NASDAQ

Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients ...

CIK

0001017491

ISIN

US81577F2083

CUSIP

81577F109

Address

300 Park Avenue

Phone

646 293 2100

Country

US

Employee

10

IPO Date

Apr 19, 1999

Summary

CIK

0001017491

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

81577F109

ISIN

US81577F2083

Country

US

Price

0.84

Beta

1.9

Volume Avg.

90.93k

Market Cap

2.15M

Shares

-

52-Week

0.8-398.4

DCF

-1.89

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.02

P/B

-

Website

https://seelostherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest SEEL News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep